Camargo Pharmaceutical Services, a Cincinnati, OH, US-based drug development company specialising in the 505(b)(2) approval pathway, has expanded its research team and therapeutic expertise with the addition of Wen-Yee Choi, Jillian Orans, Vien Lai and Kathryn Kemme.
Choi and Orans completed Camargo’s spring 2014 postdoctoral internship programme and now join the company as Research Scientists. Choi specializes in cardiovascular medicine, including cardiac regeneration and bench-to-bedside research, while Orans has extensive experience in DNA mismatch repair in hereditary colon cancer, bacterial fitness and pathogenesis in infectious disease.
Lai also joins Camargo as a Research Scientist, with a focus on stem cell research and cardiovascular disease.
As Associate Director of chemistry, manufacturing and control (CMC), Kemme will provide direction and technical support for partnering contract manufacturing organisations.